Achillion Pharmaceuticals (ACHN) was Initiated by Chardan Capital Markets to “Sell” and the brokerage firm has set the Price Target at $4. Chardan Capital Markets advised their investors in a research report released on Jul 14, 2016.
Many Wall Street Analysts have commented on Achillion Pharmaceuticals. Achillion Pharmaceuticals was Upgraded by JMP Securities to ” Mkt Outperform” on Jul 7, 2016.
On the company’s financial health, Achillion Pharmaceuticals reported $-0.13 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on May 3, 2016. Analyst had a consensus of $-0.14.During the same quarter in the previous year, the company posted $-0.17 EPS.
Achillion Pharmaceuticals closed down -0.31 points or -3.35% at $8.93 with 14,00,199 shares getting traded on Wednesday. Post opening the session at $9.33, the shares hit an intraday low of $8.925 and an intraday high of $9.33 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Dec 30, 2015, Mary Kay Fenton (Chief Financial Officer) sold 43,500 shares at $10.08 per share price. According to the SEC, on Dec 30, 2015, David Apelian (Chief Medical Officer) sold 10,000 shares at $10.50 per share price. On Nov 12, 2015, Nicole Vitullo (director) sold 550,000 shares at $10.25 per share price, according to the Form-4 filing with the securities and exchange commission.
Achillion Pharmaceuticals Inc. is a biopharmaceutical company. The Company’s primary business is to discover develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus or HCV infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens including ACH-3102 a NS5A inhibitor which is under Phase II clinical development ACH-3422 a NS5B nucleotide polymerase inhibitor which is under Phase I clinical development and Sovaprevir a NS3 protease inhibitor which is under Phase II clinical development.